Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.66 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.66 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13678671 | 1.00 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11852550 | 0.99 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1525218 | 0.91 | ALDH1A1 (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL9868833 | 0.90 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL30608768 | 0.90 | LMNA (0.74) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL28197797 | 0.90 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4665032 | 0.89 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4585577 | 0.89 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4586059 | 0.89 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4450358 | 0.89 | ALDH1A1 (0.54) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022123501-A1 | PROTECTED DEOXYDIDEHYDRO-NUCLEOSIDES | VICTORIA LINK LIMITED (NZ) | 2022-06-16 | — | — | WO | claimed |
| CN-1012366-B | The preparation of cytidine(C | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-04-17 | — | — | CN | claimed |
| EP-0193903-B1 | PRODUCTION OF CYTOSINE NUCLEOSIDES | Takeda Chemical Industries, Ltd. (JP) | 1990-06-13 | — | — | EP | claimed |
| EP-0193903-A2 | Production of cytosine nucleosides | Takeda Chemical Industries, Ltd. (JP) | 1986-09-10 | — | — | EP | claimed |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| CN-116970014-B | Preparation method and application of N-heterocyclic carbene catalyzed selectively acylated nucleoside derivative | 贵州大学 | 2026-02-27 | — | — | CN | disclosed |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250171783-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-12-19 | — | — | US | disclosed |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | SAREPTA THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SAREPTA THERAPEUTICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| CN-1012366-B | The preparation of cytidine(C | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1991-04-17 | — | — | CN | disclosed |
| EP-0193903-B1 | PRODUCTION OF CYTOSINE NUCLEOSIDES | Takeda Chemical Industries, Ltd. (JP) | 1990-06-13 | — | — | EP | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0260032-A2 | Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers | AJINOMOTO CO., INC. (JP) | 1988-03-16 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| CN-86101400-A | The preparation of cytidine(C | — | 1986-09-10 | — | — | CN | disclosed |
| EP-0191869-A1 | FISH CALCITONIN DERIVATIVE, PROCESS FOR ITS PREPARATION, AND GENE SYSTEM THEREFOR | HODOGAYA CHEMICAL COMPANY, LIMITED (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415857-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | COL2A1, COL14A1, UPF1 | LMNA 259/4885THRB 2845/4885MTOR 4864/4885 |
| US-12139709-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | GAA, GBA3, GBA1 | LMNA 352/4885THRB 3335/4885MTOR 4712/4885 |
| US-12121532-B2 | Modified antisense oligomers for exon inclusion in spinal muscular atrophy | SMN1; SMN2, UPF1, RBM17 | LMNA 439/4885THRB 3399/4885MTOR 4059/4885 |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | DCLRE1B, OGG1, DCTD | LMNA 1735/4885THRB 1813/4885MTOR 3503/4885 |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | LMNA 352/4885THRB 3335/4885MTOR 4712/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | LMNA 439/4885THRB 3399/4885MTOR 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.